Journal
CURRENT MEDICAL RESEARCH AND OPINION
Volume 37, Issue 6, Pages 929-938Publisher
TAYLOR & FRANCIS LTD
DOI: 10.1080/03007995.2021.1906637
Keywords
Rheumatoid arthritis; COVID-19; anti-rheumatic; cytokines; DMARDs
Ask authors/readers for more resources
COVID-19 infection and rheumatoid arthritis share common pathological features and inflammatory cytokines, but recent studies show that RA patients are not at higher risk compared to the general population. Researchers are exploring anti-rheumatic drugs as potential therapeutic modalities for COVID-19.
In March 2020, COVID-19 infection caused by SARS-CoV-2 has been declared to be a global pandemic, where its complications, severity and mortality are reported to be due to the released inflammatory cytokines or the so-called cytokine storm. This is quite similar to that observed in the autoimmune and chronic inflammatory rheumatic disease, rheumatoid arthritis (RA). It was hypothesized that RA patients are at a higher risk of acquiring COVID-19; however, recent studies reported that they are not when compared to the rest of the population. In this review, we aim to highlight the mutual pathological features, cytokine profiles and risk factors between COVID-19 and RA. Also, many researchers are currently working to explore therapeutic agents that could aid in the eradication of COVID-19 infection. Due to the similarity between the inflammation status in COVID-19 and RA, many anti-rheumatic drugs such as hydroxychloroquine, tocilizumab, baricitinib and anakinra were proposed to be therapeutic modalities for COVID-19 infection.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available